Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Design Therapeutics, Inc. - Common Stock (NQ:DSGN)

10.20 +0.08 (+0.79%)
Streaming Delayed Price Updated: 1:09 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 79,778
Open 10.14
Bid (Size) 10.16 (100)
Ask (Size) 10.23 (200)
Prev. Close 10.12
Today's Range 10.10 - 10.40
52wk Range 2.600 - 10.97
Shares Outstanding 55,945,551
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Design Therapeutics to Participate in Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+12.1%
+12.1%
1 Month
+7.9%
+7.9%
3 Month
+34.4%
+34.4%
6 Month
+97.3%
+97.3%
1 Year
+147.0%
+147.0%

More News

Read More
News headline image
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday ↗
Via Benzinga
News headline image
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Appoints Justin Gover to Board of Directors
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller ↗
Via Benzinga
News headline image
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Top movers in Friday's pre-market session ↗
Via Chartmill
News headline image
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Design Therapeutics, Inc. - Common Stock publicly traded?
Yes, Design Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Design Therapeutics, Inc. - Common Stock trade on?
Design Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Design Therapeutics, Inc. - Common Stock?
The ticker symbol for Design Therapeutics, Inc. - Common Stock is DSGN on the Nasdaq Stock Market
What is the current price of Design Therapeutics, Inc. - Common Stock?
The current price of Design Therapeutics, Inc. - Common Stock is 10.20
When was Design Therapeutics, Inc. - Common Stock last traded?
The last trade of Design Therapeutics, Inc. - Common Stock was at 02/18/26 01:09 PM ET
What is the market capitalization of Design Therapeutics, Inc. - Common Stock?
The market capitalization of Design Therapeutics, Inc. - Common Stock is 570.64M
How many shares of Design Therapeutics, Inc. - Common Stock are outstanding?
Design Therapeutics, Inc. - Common Stock has 571M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.